Trial Profile
Phase I and pharmacokinetic study of tasidotin administered intravenously daily for five consecutive days every 3 weeks in patients with advanced solid tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2006
Price :
$35
*
At a glance
- Drugs Tasidotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 19 Jan 2006 New trial record.